PATTERNS OF CLINICAL MANAGEMENT AND RESOURCE UTILIZATION FOR POSTMENOPAUSAL HORMONE-RECEPTOR-POSITIVE HER2-NEGATIVE (HR+HER2-) ADVANCED BREAST CANCER (ABC) IN EUROPE

被引：0
|
作者：
Jerusalem, G. [1 ]
Marinsek, N. [2 ]
Ricci, J. [3 ]
Etchberger, J. [2 ]
Degun, R. [2 ]
Benelli, G. [4 ]
Saletan, S. [5 ]
Andre, F. [6 ]
机构：
[1] CHU Sart Tilman, B-4000 Liege, Belgium
[2] Navigant Consulting Inc, London, England
[3] Wellmera AG, Basel, Switzerland
[4] Novartis Farma Spa, Saronno, Italy
[5] Novartis Pharmaceut, Onco Ex Dir Clin Res Phys, E Hanover, NJ USA
[6] Inst Gustave Roussy, Breast Canc Unit, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [31] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.
    Janni, Wolfgang
    Burris, Howard A.
    Blackwell, Kimberly L.
    Hart, Lowell L.
    Chan, Arlene
    Nusch, Arnd
    Burdaeva, Olga Nikolaevna
    Alba, Emilio
    Yardley, Denise A.
    Bachelot, Thomas Denis
    Gil, Miguel J. Gil
    Richards, Donald A.
    Sparano, Joseph A.
    Kattan, Joseph Gergi
    Bourgeois, Hugues Pierre
    El Karak, Fadi Rafic
    Ramaswamy, Bhuvaneswari
    Sutradhar, Santosh C.
    Miller, Michelle Kristine
    Conte, Pier Franco
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Patterns of health care utilization and costs by chemotherapy and endocrine therapy sequencing among patients with hormone receptor positive (HR+)/HER2-negative advanced breast cancer
    Engel-Nitz, N. M.
    Hao, Y.
    Rey, G. Gomez
    Sullivan, J.
    Rogerio, J. Willemann
    [J]. CANCER RESEARCH, 2013, 73
  • [33] Solti-1718 NEREA trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-Enriched (HER2-E) advanced breast cancer (BC)
    Saura, Cristina
    Ciruelos, Eva
    Vidal, Maria
    Garrigos, Laia
    Margeli, Mireia
    Morales, Serafin
    Gonzalez-Farre, Xavier
    Salvador Bofill, Javier
    Blancas, Isabel
    Gasent, Joan M.
    Lopez-Miranda, Elena
    Godoy, Ana
    Iglesias, Maria
    Sanchez-Rovira, Pedro
    Hernao, Fernando
    Gallegos, Isabel
    Pulido, Catarina
    Alves, Sara
    Branco, Diogo
    Passos-Coelho, Jose
    Escriva-de-Romani, Santiago
    Ferrero-Cafiero, Juan M.
    Villagrasa, Patricia
    Prat, Aleix
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [34] SOLTI-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC)
    Ciruelos, Eva
    Saura, Cristina
    Gonzalez-Farre, Xavier
    Bofill, Francisco Javier Salvador
    Vidal, Maria
    Blancas, Isabel
    Lopez-Miranda, Elena
    Iglesias, Maria
    Arumi, Miriam
    Margeli, Mireia
    Pulido, Catarina
    Murillo, Serafin Morales
    Henao, Fernando
    Sanchez, Pilar
    Alves, Sara
    Ortiz, Ana Godoy
    Coelho, Jose Passos
    Escriva-de-Romani, Santiago
    Espinosa, Alejandra
    Pascual, Tomas
    Prat, Aleix
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [35] Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC)
    Ciruelos, Eva
    Saura, Cristina
    Gonzalez-Farre, Xavier
    Bofill, Javier Salvador
    Vidal, Maria
    Blancas, Isabel
    Lopez-Miranda, Elena
    Iglesias, Maria
    Arumi, Miriam
    Margeli, Mireia
    Pulido, Catarina
    Morales, Serafin
    Henao, Fernando
    Sanchez, Pilar
    Alves, Sara
    Branco, Diogo
    Gasent, Joan Manel
    Sanchez-Rovira, Pedro
    Godoy, Ana
    Passos-Coelho, Jose L.
    Escriva-De-Romani, Santiago
    Ferrero-Cafiero, Juan M.
    Pascual, Tomas
    Prat, Aleix
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [36] Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer
    Andre, Fabrice
    Neven, Patrick
    Marinsek, Nina
    Zhang, Jie
    Baladi, Jean-Francois
    Degun, Ravi
    Benelli, Giancarlo
    Saletan, Stephen
    Jerusalem, Guy
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (06) : 1007 - 1016
  • [37] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Kim, Esther S.
    Scott, Lesley J.
    [J]. TARGETED ONCOLOGY, 2017, 12 (03) : 373 - 383
  • [38] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Esther S. Kim
    Lesley J. Scott
    [J]. Targeted Oncology, 2017, 12 : 373 - 383
  • [39] Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials
    El Sayed, Rola
    El Jamal, Lara
    El Iskandarani, Sarah
    Kort, Jeries
    Salam, Mahmoud Abdel
    Assi, Hazem
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [40] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    [J]. CANCER TREATMENT REVIEWS, 2024, 123
12345